ClinicalTrials.gg
TerminatedNCT00642616Updated Apr 14, 2017Results posted

Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease

A Phase 3 interventional study of Technosphere® Insulin and Usual Care in Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus and Moderate Chronic Obstructive Pulmonary Disease, sponsored by Mannkind Corporation. Terminated at 21 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-04-14.

Sponsored by Mannkind Corporation · Phase 3, Interventional, and Treatment

Why this study was terminated
Terminated upon recommendation of the Data Safety Monitoring Board (DSMB)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 — 1 open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 1.

Enrollment
21st of 35
34 · median 74
Started
2009
the only one that year
Phase 3
17 of 35
none open now
Registered
18th of 35
by date
Lead sponsor
14 of 35
Mannkind Corporation

Among the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, this one is the 21st largest by enrollment, is the only one that started in 2009, is one of 17 in phase 3, and was the 18th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

1 of the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Insulin, Regular, Human

Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

Examine the effects of TI in combination with an anti-diabetic regimen including inhaled insulin versus anti-diabetic treatment without inhaled insulin on lung function \& pulmonary safety

03

Conditions studied

  • Type 1 Diabetes Mellitus
  • Type 2 Diabetes Mellitus
  • Moderate Chronic Obstructive Pulmonary Disease
  • Asthma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Asthma

  • Physician diagnosis of asthma with history of any or all of the following: recurrent wheezing, recurrent chest tightness, recurrent difficulty breathing, or cough, particularly worse at nighttime
  • Never smoked or former smokers (= 6 months since cessation)
  • ≥18 years of age
  • Prebronchodilator Forced Expiratory Volume in 1sec () ≥ 60% Third National Health and Nutrition Examination Survey (NHANES III) predicted, prebronchodilator total lung capacity (TLC) ≥ 80% predicted Intermountain Thoracic Society (ITS), and prebronchodilator single breath carbon monoxide diffusing capacity of the lung (DLco) (unc) ≥70% predicted (Miller)
  • \< 30% day-to-day variability in daily morning Peak expiratory Volume (PEF) during the 2-week run-in period
  • Significant improvement in pre- to postbronchodilator spirometry (defined as an increase from baseline of ≥ 12% and ≥ 200 mL in FEV1 or Forced Vital Capacity [FVC]) at Screening/Visit 1 or documented significant improvement in pre- to postbronchodilator spirometry (as defined above) within past 12 months in subject's medical records or a documented positive methacholine challenge test within the past 12 months

  • Physician diagnosis of COPD (including emphysema and/or chronic bronchitis), history of dyspnea and/or intermittent or daily chronic cough with or without sputum production, not attributable to any other known cause
  • Former smoker (≥ 6 months since cessation) with smoking history of ≥ 10 pack years
  • ≥40 years of age
  • Postbronchodilator FEV1/FVC ratio \< 70%
  • Postbronchodilator FEV1 ≥ 50% NHANES III predicted, total lung capacity (TLC) ≥ 80% predicted ITS, and DLco (unc) ≥ 50% predicted (Miller)

Both

  • Clinical diagnosis of Type1 or 2 diabetes mellitus for ≥ 12 months and no change in anti-diabetic regiment for at least 90-days prior to screening
  • of, \< 39 kg/m2
  • Urine cotinine level ≤ 100ng/dL
  • Clinical diagnosis of obstructive lung disease
  • > 6.5% ≤ 11.5%

Exclusion criteria

Exclusion Criteria:

  • History of pulmonary exacerbation within 8 weeks of screening/V1 or between V1 and V2
  • Use of systemic or antibiotics for respiratory illness within 8 weeks of screening/V1 OR between V1 and V2
  • Increase from baseline in the use of short-acting bronchodilator or short-acting anticholinergic agents, or the combination of the 2, by ≥6 puffs or ≥3 nebulizer treatments per day for ≥ 2 days
  • Treatment with supplemental oxygen therapy, room air oxygen saturation, 94% or history of intubation or ICU admission for respiratory illness in the past 5 yrs.
  • Greater than 2 hospitalizations or ER or urgent care visits or required >3 courses of systemic steroid in the past 12 months for respiratory illness
  • Use of Symlin® (pramlintide acetate) within the preceding 90 days
  • Two or more severe hypoglycemic episodes within 6 months of screening or episode of severe hypoglycemia between Screening and Baseline
  • Previous exposure to any inhaled insulin product
  • Currently using an insulin delivery pump
  • Requires significant change (define as initiation of a new medication or change in the dose or frequency of the controller medications) in the asthma or therapeutic regimen within 8 weeks of Screening/Visit 1 (Week -4) or between Visit 1 and Baseline/Visit 2
  • Severe complications of diabetes mellitus, in the opinion of the PI or sub-investigator, including symptomatic autonomic neuropathy; disabling peripheral neuropathy; active proliferative retinopathy; nephropathy with renal failure, renal transplant and/or dialysis; history of foot ulcers; nontraumatic amputations due to gangrene; and/or vascular claudication
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Technosphere® Insulin (Asthma)

    Technosphere® Insulin Inhalation Powder administered prandially in diabetic participants with Asthma

    Drug: Technosphere® Insulin

  • Active comparator
    Usual Care (Asthma)

    Usual anti diabetic care in Diabetic participants with Asthma

    Drug: Usual Care

  • Experimental
    Technosphere® Insulin (COPD)

    Technosphere® Insulin Inhalation Powder administered prandially in diabetic participants with Chronic Obstructive Pulmonary disease (COPD)

    Drug: Technosphere® Insulin

  • Active comparator
    Usual Care (COPD)

    Usual anti diabetic care in Diabetic participants with Chronic Obstructive Pulmonary disease (COPD)

    Drug: Usual Care

Interventions

  • Technosphere® Insulin delivered with Gen 2 inhaler with doses individualized for each participant in combination with an antidiabetic regimen of insulin and/or oral antidiabetic agents

    Also known as: Afrezza

  • DrugUsual Care

    Type 1 diabetics: long-acting (basal) insulin plus rapid-acting insulin, or pre-mix insulin Type 2 diabetics: oral anti-diabetic medications with or without long-acting (basal) insulin

06

What researchers measure

Primary outcomes

  1. Change in Post-bronchodilator FEV1 From Baseline to Week 52

    Post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) is measured at the pulmonary function laboratory.

    Time frame: 52 Weeks

Secondary outcomes

  1. Number of Participants With Asthma Exacerbation by Treatment Arm

    Number of participants who experienced worsening of asthma symptoms

    Time frame: Baseline to Week 52

  2. Number of Participants With COPD Exacerbation by Treatment Arm

    Number of participants who experienced worsening of COPD symptoms

    Time frame: Baseline to Week 52

  3. Change in HbA1C From Baseline to Week 52

    Time frame: Baseline, week 52

07

Results

Posted Feb 15, 2016
Limitations and caveats
- Early termination of trial leading to small numbers of subjects analyzed

Participant flow

A total of 517 participants were screened in 5 countries . First participant was screened in March 2009.

Participant flow — Overall Study
MilestoneTechnosphere® Insulin (Asthma)Usual Care (Asthma)Technosphere® Insulin (COPD)Usual Care (COPD)
Started9898
Completed0101
Not completed9797
Withdrew: Adverse event2010
Withdrew: Study terminated by sponsor7645
Withdrew: Withdrawal by subject0111
Withdrew: Protocol violation0020
Withdrew: Physician decision0011

Outcome measures

PrimaryChange in Post-bronchodilator FEV1 From Baseline to Week 52

Post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) is measured at the pulmonary function laboratory.

Time frame:
52 Weeks

No measurements were reported for this outcome.

SecondaryNumber of Participants With Asthma Exacerbation by Treatment Arm

Number of participants who experienced worsening of asthma symptoms

Time frame:
Baseline to Week 52
Reported as:
Number · participants
Number of Participants With Asthma Exacerbation by Treatment Arm
participantsTechnosphere® Insulin (Asthma)Usual Care With Anti-diabetic Agents (Asthma)Technosphere® Insulin (COPD)Usual Care With Anti-diabetic Agents (COPD)
Exacerbation of Asthma11——
No Exacerbation of Asthma87——
SecondaryNumber of Participants With COPD Exacerbation by Treatment Arm

Number of participants who experienced worsening of COPD symptoms

Time frame:
Baseline to Week 52
Reported as:
Number · participants
Number of Participants With COPD Exacerbation by Treatment Arm
participantsTechnosphere® Insulin (Asthma)Usual Care With Anti-diabetic Agents (Asthma)Technosphere® Insulin (COPD)Usual Care With Anti-diabetic Agents (COPD)
COPD Exacerbation——31
No Exacerbation——67
SecondaryChange in HbA1C From Baseline to Week 52
Time frame:
Baseline, week 52

No measurements were reported for this outcome.

Adverse events

Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to 30 days after the last study visit or study related procedure was performed regardless of seriousness or relationship to investigational product. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Technosphere® Insulin (Asthma)—2/9 (22.2%)8/9 (88.9%)
Usual Care With Anti-diabetic Agents (Asthma)—0/8 (0%)7/8 (87.5%)
Technosphere® Insulin (COPD)—0/9 (0%)4/9 (44.4%)
Usual Care With Anti-diabetic Agents (COPD)—0/8 (0%)6/8 (75%)
Most frequent serious events
Most frequent serious events
EventTechnosphere® Insulin (Asthma)Usual Care With Anti-diabetic Agents (Asthma)Technosphere® Insulin (COPD)Usual Care With Anti-diabetic Agents (COPD)
AsthmaRespiratory, thoracic and mediastinal disorders1/90/80/90/8
Intestinal obstructionGastrointestinal disorders1/90/80/90/8
HypercalcaemiaMetabolism and nutrition disorders1/90/80/90/8
HypoglycaemiaMetabolism and nutrition disorders1/90/80/90/8
B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/90/80/90/8
Most frequent other events
Showing 10 of 47
Most frequent other events
EventTechnosphere® Insulin (Asthma)Usual Care With Anti-diabetic Agents (Asthma)Technosphere® Insulin (COPD)Usual Care With Anti-diabetic Agents (COPD)
HypoglycemiaMetabolism and nutrition disorders2/90/81/93/8
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/90/83/91/8
Urinary Tract InfectionInfections and infestations0/92/80/90/8
BronchitisInfections and infestations2/90/80/90/8
CoughRespiratory, thoracic and mediastinal disorders1/90/82/90/8
AstheniaGeneral disorders0/91/80/90/8
AsthmaRespiratory, thoracic and mediastinal disorders0/91/80/90/8
Diabetes mellitusMetabolism and nutrition disorders0/91/80/90/8
DyslipidaemiaMetabolism and nutrition disorders0/91/80/90/8
Hot flushVascular disorders0/91/80/90/8

Baseline characteristics

Subjects who received at least one dose of study medication

Age, Continuous
Age, Continuous(years)Technosphere® Insulin (Asthma)Usual Care (Asthma)Technosphere® Insulin (COPD)Usual Care (COPD)Total
Mean69.00 ± 7.2649.75 ± 15.7367.44 ± 8.3868.88 ± 8.2064.03 ± 12.71
Sex: Female, Male
Sex: Female, Male(Participants)Technosphere® Insulin (Asthma)Usual Care (Asthma)Technosphere® Insulin (COPD)Usual Care (COPD)Total
Female642113
Male347721
08

Study locations

21 sites
  • Mission Hills, California 91345, United States
  • San Diego, California 92117, United States
  • Palm Harbor, Florida 34684, United States
  • Flint, Michigan 48504, United States
  • Morehead City, North Carolina 28557, United States
  • Medford, Oregon 97504, United States
  • Greenville, South Carolina 29615, United States
  • Spartanburg, South Carolina 29302, United States
  • Dallas, Texas 75225, United States
  • Dallas, Texas 75231, United States
  • Federal Way, Washington 98003, United States
  • Tacoma, Washington 98405, United States
  • Yaroslavl, RUS 150002, Russian Federation
  • Kemerovo, RU 650066, Russian Federation
  • Moscow, RU 105120, Russian Federation
  • St Petersburg, RU 198013, Russian Federation
  • St. Petersburg, RU 191015, Russian Federation
  • St. Petersburg, RU 191119, Russian Federation
  • St. Petersburg, RU 194354, Russian Federation
  • Kiev, UA 04114, Ukraine
  • Kyiv, UA 01021, Ukraine
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2016, 1 year 3 months after primary completion. A results delay was requested in Jun 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2008
First posted
Mar 25, 2008
Start
Mar 2009
Primary completionActual
Nov 2014
CompletionActual
Nov 2014
Results delay requested
Jun 9, 2009
Results first posted
Feb 15, 2016
Last update
Apr 14, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00642616
Responsible party
Sponsor
First posted
Mar 25, 2008
Start date
Mar 2009
Primary completion
Nov 2014
Completion
Nov 2014
Results posted
Feb 15, 2016
Last update
Apr 14, 2017

Study contacts

Chief Medical Officer
study chair · Mannkind Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Regular, Human

Start the discussion